Predict your next investment

Venture Capital
section32.com

See what CB Insights has to offer

Investments

91

Portfolio Exits

14

Funds

4

About Section 32

Section 32 is a fund with a focus on biotech and healthcare startups. The fund was established by Bill Maris, the former founder and CEO of GV (fka Google Ventures).

Section 32 Headquarter Location

2033 San Elijo Ave. #565

San Diego, California, 92007,

United States

858-633-3232

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Section 32 News

Section 32 Expands Investment Team with the Addition of Carlos Solórzano, Ph.D.

Jan 26, 2022

Section 32 Expands Investment Team with the Addition of Carlos Solórzano, Ph.D. SAN DIEGO, January 25, 2022-- Section 32, a venture capital fund investing at the frontiers of technology and healthcare, announced today the addition of Carlos Solórzano, Ph.D., as Senior Principal to support the continued growth of its investing team. Carlos, an accomplished scientist, equity research analyst and life sciences venture investor, will be based at Section 32's location in Los Altos. "It's a pleasure to welcome Carlos to our team," said Section 32 Managing Partner Andy Harrison. "Carlos' broad experiences evaluating healthcare investment opportunities through the lenses of investment banking, venture and corporate development complement our growing investment team. We look forward to Carlos' contributions to our efforts as we build our portfolio of technology and healthcare companies." As a Senior Principal at Section 32, Carlos focuses on the firm's investment sourcing, diligence, and deal execution efforts. Prior to Section 32, Carlos served as a Senior Associate for Pivotal bioVenture Partners, a life sciences venture fund, where he led and participated in diligence, term sheet negotiation, deal syndication and other deal processes for its life sciences portfolio. Previously, Carlos was an Associate Director, Corporate Strategy and Business Development for Ultragenyx Pharmaceutical, where he worked on competitive intelligence, as well as portfolio development, commercial partnerships and strategy. Carlos also worked as an equity research associate at Deutsche Bank and Oppenheimer & Co. covering small-, mid- and large-cap biotech companies. Carlos earned his Ph.D. in Pharmacology and Toxicology from UC Irvine and was an NIH postdoctoral scholar, Neuroscience, at UC San Francisco, where he investigated the neurobiology of pain and itch. He received a B.S. in Chemical Engineering from Cal Poly Pomona. About Section 32 Section 32 is a venture capital fund investing at the frontiers of technology and healthcare. Founded by Bill Maris, the team has vast experience building iconic companies. The firm's goal is to improve the human condition by accelerating the discovery, development and distribution of important technologies and life-saving medicines. Section 32 invests across the entirety of technology and life sciences. This includes software, cybersecurity, advanced communications and computation, space, climate change related technologies, machine learning, artificial intelligence, biotechnology, therapeutics, advanced diagnostics, precision medicine, genomics and more. For more information, please visit Section32.com

Section 32 Investments

91 Investments

Section 32 has made 91 investments. Their latest investment was in Character Biosciences as part of their Series A on May 5, 2022.

CBI Logo

Section 32 Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/17/2022

Series A

Character Biosciences

$18M

Yes

2

5/12/2022

Series B

Legacy

$25M

No

2

5/10/2022

Series B

MOMA Therapeutics

$150M

Yes

7

5/9/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/25/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/17/2022

5/12/2022

5/10/2022

5/9/2022

4/25/2022

Round

Series A

Series B

Series B

Series B

Series C

Company

Character Biosciences

Legacy

MOMA Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$18M

$25M

$150M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

7

10

10

Section 32 Portfolio Exits

14 Portfolio Exits

Section 32 has 14 portfolio exits. Their latest portfolio exit was Current Health on October 12, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/12/2021

Acquired

$99M

3

9/24/2021

IPO

$99M

Public

21

9/7/2021

Acquired

$99M

5

8/6/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

7/22/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/12/2021

9/24/2021

9/7/2021

8/6/2021

7/22/2021

Exit

Acquired

IPO

Acquired

Acq - Pending

Reverse Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

3

21

5

10

10

Section 32 Fund History

4 Fund Histories

Section 32 has 4 funds, including Section 32 Fund II.

Closing Date

Fund

Fund Type

Status

Amount

Sources

2/21/2019

Section 32 Fund II

Early-Stage Venture Capital

Open

$199.35M

6

5/22/2017

Section 32 Fund I

Subscribe to see more

Subscribe to see more

$99M

10

Section 32 Fund IV

10

Section 32 Fund III

10

Closing Date

2/21/2019

5/22/2017

Fund

Section 32 Fund II

Section 32 Fund I

Section 32 Fund IV

Section 32 Fund III

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Open

Subscribe to see more

Amount

$199.35M

$99M

Sources

6

10

10

10

Section 32 Team

4 Team Members

Section 32 has 4 team members, including current Chief Financial Officer, Chief Operating Officer, Nina Ebert.

Name

Work History

Title

Status

Nina Ebert

Trinity Ventures, Silicon Valley Bank, Health Evolution Partners, Labrador Ventures, Saints Capital, PeoplePC, Montgomery, and Goldman Sachs

Chief Financial Officer, Chief Operating Officer

Current

Andrew Harrison

Google, Northwater Capital Management, Celtic House Venture Partners, RBC Venture Partners, and National Research Council Canada

Managing Partner

Current

Steve Kafka

Managing Partner

Current

Michael Pellini

Managing Partner

Current

Name

Nina Ebert

Andrew Harrison

Steve Kafka

Michael Pellini

Work History

Trinity Ventures, Silicon Valley Bank, Health Evolution Partners, Labrador Ventures, Saints Capital, PeoplePC, Montgomery, and Goldman Sachs

Google, Northwater Capital Management, Celtic House Venture Partners, RBC Venture Partners, and National Research Council Canada

Title

Chief Financial Officer, Chief Operating Officer

Managing Partner

Managing Partner

Managing Partner

Status

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.